サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1780774

ファブリー病治療の世界市場

Fabry Disease Treatment

出版日
ページ情報
英文 367 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
ファブリー病治療の世界市場
出版日: 2025年07月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 367 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ファブリー病治療の世界市場は2030年までに44億米ドルに達する見込み

2024年に27億米ドルと推定されるファブリー病治療の世界市場は、分析期間2024-2030年にCAGR 8.2%で成長し、2030年には44億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである酵素補充療法は、CAGR 10.8%を記録し、分析期間終了時には17億米ドルに達すると予測されます。シャペロン治療分野の成長率は、分析期間中CAGR 6.4％と推定されます。

米国市場は7億3,780万米ドルと推定、中国はCAGR13.2％で成長予測

米国のファブリー病治療市場は、2024年に7億3,780万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億5,860万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と8.0％と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界のファブリー病治療市場- 主要動向と促進要因まとめ

ファブリー病とは何か、なぜ効果的な治療が重要なのか？

ファブリー病は、GLA遺伝子の変異によって引き起こされる稀な遺伝病であり、α-ガラクトシダーゼA（α-Gal A）酵素の欠損につながります。この酵素はグロボトリアオシルセラミド（Gb3またはGL-3）と呼ばれる脂肪物質を分解するのに重要な働きをします。この酵素が欠乏または完全に欠落すると、心臓、腎臓、神経系などの重要な臓器に有害な脂質が蓄積し、生命を脅かす合併症を引き起こします。ファブリー病は進行性であるため、早期に効果的な治療を行うことが、症状を管理し、臓器障害を遅らせ、患者のQOLを改善するために重要です。

ファブリー病の治療は主に、欠損した酵素を補充または増強し、病気の進行を遅らせ、関連する症状を管理することに重点を置いています。歴史的には、酵素補充療法（ERT）が標準治療であり、アガルシダーゼ・アルファ（Replagal）やアガルシダーゼ・ベータ（Fabrazyme）といったFDA承認の治療薬がGb3蓄積の抑制に役立ってきました。しかし、高額な費用、免疫反応、頻繁な点滴注射などの制限から、シャペロン療法や基質減少療法（SRT）などの代替療法の開発が進められています。また、最近の遺伝子治療の導入は、1回限りの治療法として、長期的な疾患管理への希望をもたらす可能性があります。

遺伝子・分子治療の進歩はどのような変革をもたらすのか？

遺伝子治療は、ファブリー病治療において最も有望なフロンティアの一つとして浮上しています。従来の酵素補充療法とは異なり、遺伝子治療は、GLA遺伝子の機能的コピーを患者細胞に送り込むことによって、根本的な遺伝的欠陥を修正することを目的としています。臨床試験はすでに有望な結果を示しており、FLT190やAVROBIOのAVR-RD-01のような治験中の治療法は、持続的な酵素活性とGb3レベルの低下を示しています。これらの治療法は、生涯にわたる酵素点滴の必要性をなくし、1回で治癒する可能性を秘めています。

治療におけるもう一つの大きな革新は、薬理学的シャペロン療法であり、これは特定の変異を有する患者において残存酵素の安定性と機能を高めるものです。FDAが承認した最初のシャペロン療法であるミガラスタット（ガラフォールド）は、ERTに代わる経口薬であり、利便性が高く、点滴に関連する合併症を軽減します。さらに、Gb3の産生を制限し、疾患の進行を遅らせる方法として、基質減少療法（SRT）が検討されています。これらの治療法は、ERTが効きにくい患者や経口薬を好む患者に代替療法を提供するものです。

ファブリー病治療市場にはどのような課題と機会が存在するか？

大きな進歩にもかかわらず、ファブリー病治療にはいくつかの課題が残っています。最も大きな障害の一つは、症状が他の一般的な疾患と間違われることが多いため、早期診断です。多くの患者が適切な治療を受けるのが遅れ、不可逆的な臓器障害を引き起こしています。遺伝子スクリーニングプログラムと新生児スクリーニングの取り組みを強化する努力は、症例を早期に発見し、転帰を改善するために極めて重要です。

もう一つの課題は、治療へのアクセスや治療費の安さです。ファブリー病の治療、特にERTと遺伝子治療は非常に高価であるため、包括的なヘルスケア保険に加入していない多くの患者には手が届かないです。このため、希少疾患治療に対する償還政策や資金援助を支援する患者アドボカシーや政府のイニシアチブが増加しています。さらに、製薬会社は費用対効果の高い代替品を提供し、治療効果を高めるために、バイオシミラーや次世代酵素療法を模索しています。

ファブリー病治療市場の成長を促すものは何か？

ファブリー病治療市場の成長は、遺伝子治療の技術的進歩、経口療法の採用増加、希少疾患研究プログラムの拡大など、いくつかの要因によって牽引されています。新規治療に対する規制当局の承認やファスト・トラック指定の増加は医薬品開発を加速させ、新しい治療法をより速いペースで利用できるようにしています。さらに、製薬企業との共同研究や提携がイノベーションを促進し、現在の治療法の限界に対処する次世代治療法の開発につながっています。

認知度向上キャンペーンや遺伝子検査の進歩も、早期診断と治療開始を可能にすることで市場を拡大しています。さらに、新興市場におけるヘルスケアインフラの拡充は、ファブリー病治療へのアクセスを向上させ、より多くの患者がタイムリーで効果的な治療を受けられるようにしています。研究が進むにつれて、CRISPRベースの遺伝子編集、高度な生物製剤、個別化医療アプローチの統合は、患者の転帰の改善と長期的な疾患管理を提供し、情勢を一変させると予想されます。

セグメント

治療（酵素補充療法、シャペロン治療、基質低減療法、その他のファブリー病治療）、投与経路（静脈内経路、経口経路）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • 4D Molecular Therapeutics
  • Amicus Therapeutics, Inc.
  • AVROBIO, Inc.
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Codexis, Inc.
  • Freeline Therapeutics Holdings PLC
  • Genzyme Corporation（Sanofi Genzyme）
  • Greenovation Biotech GmbH
  • Idorsia Pharmaceuticals Ltd
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • M6P Therapeutics
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Yuhan Corporation

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30885

Global Fabry Disease Treatment Market to Reach US$4.4 Billion by 2030

The global market for Fabry Disease Treatment estimated at US$2.7 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Chaperone Treatment segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$737.8 Million While China is Forecast to Grow at 13.2% CAGR

The Fabry Disease Treatment market in the U.S. is estimated at US$737.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$958.6 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Fabry Disease Treatment Market - Key Trends & Drivers Summarized

What Is Fabry Disease and Why Is Effective Treatment Crucial?

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, leading to a deficiency of the alpha-galactosidase A (α-Gal A) enzyme. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3). When the enzyme is deficient or completely absent, harmful lipid accumulation occurs in vital organs such as the heart, kidneys, and nervous system, leading to life-threatening complications. Fabry disease is progressive, meaning early and effective treatment is critical to managing symptoms, slowing organ damage, and improving patients' quality of life.

Fabry disease treatments primarily focus on replacing or enhancing the missing enzyme, slowing disease progression, and managing associated symptoms. Historically, Enzyme Replacement Therapy (ERT) has been the standard of care, with FDA-approved treatments such as agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme) helping to reduce Gb3 accumulation. However, limitations such as high costs, immune responses, and frequent intravenous infusions have driven the development of alternative therapies, including chaperone therapy and substrate reduction therapy (SRT). The recent introduction of gene therapy is also paving the way for a potential one-time treatment approach, offering hope for long-term disease management.

How Are Advancements in Gene and Molecular Therapy Transforming Fabry Disease Treatment?

Gene therapy is emerging as one of the most promising frontiers in Fabry disease treatment. Unlike traditional enzyme replacement therapy, gene therapy aims to correct the underlying genetic defect by delivering functional copies of the GLA gene into patient cells. Clinical trials are already showing promising results, with investigational therapies such as FLT190 and AVROBIO's AVR-RD-01 demonstrating sustained enzyme activity and reduced Gb3 levels. These therapies hold the potential for a one-time curative solution, eliminating the need for lifelong enzyme infusions.

Another major innovation in treatment is pharmacological chaperone therapy, which enhances the stability and function of the residual enzyme in patients with specific mutations. The first FDA-approved chaperone therapy, migalastat (Galafold), offers an oral alternative to ERT, providing greater convenience and reducing infusion-related complications. Additionally, substrate reduction therapies (SRTs) are being explored as a way to limit the production of Gb3, thereby slowing disease progression. These therapies provide an alternative for patients who do not respond well to ERT or prefer oral medications.

What Challenges and Opportunities Exist in the Fabry Disease Treatment Market?

Despite significant advancements, several challenges remain in Fabry disease treatment. One of the biggest obstacles is early diagnosis, as symptoms are often mistaken for other common conditions. Many patients experience delays in receiving proper treatment, leading to irreversible organ damage. Efforts to enhance genetic screening programs and newborn screening initiatives are crucial to identifying cases earlier and improving outcomes.

Another challenge is treatment accessibility and affordability. Fabry disease treatments, particularly ERT and gene therapy, are extremely expensive, making them inaccessible to many patients without comprehensive healthcare coverage. This has led to an increase in patient advocacy and government initiatives to support reimbursement policies and funding for rare disease treatments. Additionally, pharmaceutical companies are exploring biosimilar and next-generation enzyme therapies to provide cost-effective alternatives and enhance treatment efficacy.

What Is Driving Growth in the Fabry Disease Treatment Market?

The growth in the Fabry disease treatment market is driven by several factors, including technological advancements in gene therapy, the increasing adoption of oral therapies, and the expansion of rare disease research programs. The rise in regulatory approvals and fast-track designations for novel treatments has accelerated drug development, making new therapies available at a faster pace. Furthermore, pharmaceutical collaborations and partnerships are fostering innovation, leading to the development of next-generation therapies that address the limitations of current treatments.

Increasing awareness campaigns and genetic testing advancements are also expanding the market by enabling earlier diagnosis and treatment initiation. Additionally, expanded healthcare infrastructure in emerging markets is improving access to Fabry disease therapies, ensuring that more patients receive timely and effective treatment. As research progresses, the integration of CRISPR-based gene editing, advanced biologics, and personalized medicine approaches is expected to revolutionize the Fabry disease treatment landscape, offering better patient outcomes and long-term disease control.

SCOPE OF STUDY:

The report analyzes the Fabry Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy, Other Fabry Disease Treatment); Administration Route (Intravenous Route, Oral Route); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 4D Molecular Therapeutics
  • Amicus Therapeutics, Inc.
  • AVROBIO, Inc.
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Codexis, Inc.
  • Freeline Therapeutics Holdings PLC
  • Genzyme Corporation (Sanofi Genzyme)
  • Greenovation Biotech GmbH
  • Idorsia Pharmaceuticals Ltd
  • ISU Abxis Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • M6P Therapeutics
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Yuhan Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Fabry Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Fabry Disease Due to Improved Genetic Testing Drives Demand for Specialized Therapies
    • Growth in Enzyme Replacement Therapies (ERT) and Oral Chaperone Treatments Expands Therapeutic Options
    • Increasing Regulatory Approvals of New Molecules and Biologics Strengthens Market Innovation
    • Expansion of Patient Support and Advocacy Programs Enhances Early Diagnosis and Access to Treatment
    • Rising R&D in Gene Therapy and mRNA Platforms Throws the Spotlight on Long-Term Disease-Modifying Approaches
    • Global Awareness Campaigns for Rare and Lysosomal Storage Disorders Fuel Fabry Disease Identification
    • Development of Pediatric-Specific Formulations and Dosing Regimens Promotes Age-Appropriate Care
    • Availability of Biomarker-Based Monitoring Supports Personalized Dosing and Disease Progression Management
    • Expansion of Specialty Pharmacies and Hospital Networks Improves Geographic Reach of Therapies
    • Collaborations Between Pharma Companies and Research Institutions Accelerate Novel Therapy Development
    • Shift From Intravenous to Oral Therapies Improves Patient Compliance and At-Home Care Models
    • Growing Pipeline of Fabry Disease Candidates With Improved Safety Profiles Enhances Clinical Acceptance
    • Increased Use of Real-World Evidence and Longitudinal Data Strengthens Health Outcomes Analysis
    • Rising Prevalence of Misdiagnosed Cases Promotes Multi-Specialty Diagnostic Pathways and Physician Education
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fabry Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chaperone Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chaperone Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chaperone Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Substrate Reduction Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Fabry Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Intravenous Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Intravenous Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Fabry Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Fabry Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Fabry Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Fabry Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Fabry Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Fabry Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Fabry Disease Treatment by Treatment - Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Fabry Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy, Chaperone Treatment, Substrate Reduction Therapy and Other Fabry Disease Treatment for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Fabry Disease Treatment by Administration Route - Intravenous Route and Oral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Fabry Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Route and Oral Route for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Fabry Disease Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Fabry Disease Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION